• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cortexyme Inc.

    5/20/22 4:06:45 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRTX alert in real time by email
    S-8 1 d265791ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on May 20, 2022

    Registration No.333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Cortexyme, Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   90-1024039

    (State or other jurisdiction of

    Incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

     

    269 East Grand Ave.

    South San Francisco, CA 94080

    (Address of principal executive offices) (Zip code)

     

     

    Cortexyme, Inc. 2022 Inducement Plan

    Novosteo Inc. 2019 Equity Incentive Plan

    (Full titles of the plans)

     

     

    Dirk Thye

    Chief Executive Officer

    Cortexyme, Inc.

    269 East Grand Ave.

    South San Francisco, CA 94080

    (415) 910-5717

    (Name and address of agent for service) (Telephone number, including area code, of agent for service)

     

     

    Copies to:

    Gordon K. Ho

    Cooley LLP

    3175 Hanover Street

    Palo Alto, California 94304

    (650) 843-5000

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☒    Accelerated filer   ☐
    Non-accelerated filer   ☐    Smaller reporting company   ☐
       Emerging growth company   ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section7(a)(2)(B) of the Securities Act.  ☐

     

     

     


    EXPLANATORY NOTE

    On May 19, 2022, a wholly owned subsidiary of Cortexyme, Inc. (the “Registrant”) merged (the “First Merger”) with and into Novosteo Inc., a Delaware corporation (“Novosteo”) pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of May 9, 2022 (the “Merger Agreement”), by and among the Registrant, Novosteo and certain other parties. Pursuant to the Merger Agreement, each option to purchase shares of Novosteo’s common stock that was unexpired, unexercised and outstanding immediately prior to the effective time of the First Merger under the Novosteo Inc. 2019 Equity Incentive Plan (the “Novosteo Plan”), whether or not vested, was converted into and became an option to purchase shares of the Registrant’s common stock, and the Registrant assumed the Novosteo Plan. The Registrant is filing this Registration Statement for the purpose of registering 545,001 shares of the Registrant’s common stock that may be offered or issued pursuant to awards granted or that may in the future be granted under the Novosteo Plan.

    The Registrant is also filing this Registration Statement for the purpose of registering 4,000,000 additional shares of the Registrant’s common stock that may be offered or issued under the Cortexyme, Inc. 2022 Inducement Plan.

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participant in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

    PART II

    ITEM 3. INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

    The following documents filed by Registrant with the Securities and Exchange Commission (the “SEC”) are incorporated by reference into this Registration Statement:

    (a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the SEC on March 1, 2022;

    (b) The information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the fiscal year ended December  31, 2021, from the Registrant’s Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 27, 2022;

    (c) The Registrant’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022, filed with the SEC on May 10, 2022;

    (d) The Registrant’s Current Reports on Form 8-K filed with the SEC on January 26, 2022, February  2, 2022, March 15, 2022, May 2, 2022, May  10, 2022, May  12, 2022 and May 20, 2022;

    (e) All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above; and

    (f) The description of the Registrant’s common stock contained in the registration statement on Form 8-A registering the Registrant’s common stock under Section 12 of the Exchange Act filed with the SEC on May 1, 2019, including any amendments or reports filed for purposes of updating such description.

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior


    to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    ITEM 4. DESCRIPTION OF SECURITIES

    Not applicable.

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

    Not applicable.

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

    The Registrant has entered into indemnification agreements with each of its current directors and executive officers. These agreements require the Registrant to indemnify these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to the Registrant, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. The Registrant also intends to enter into indemnification agreements with its future directors and executive officers.

    Section 145 of the Delaware General Corporation Law provides that a corporation may indemnify directors and officers as well as other employees and individuals against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with any threatened, pending or completed actions, suits or proceedings in which such person is made a party by reason of such person being or having been a director, officer, employee or agent to the Registrant. The Delaware General Corporation Law provides that Section 145 is not exclusive of other rights to which those seeking indemnification may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise. The Registrant’s amended and restated bylaws provide for indemnification by the Registrant of its directors, officers and employees to the fullest extent permitted by the Delaware General Corporation Law.

    Section 102(b)(7) of the Delaware General Corporation Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director’s duty of loyalty to the corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) for unlawful payments of dividends or unlawful stock purchases, redemptions or other distributions, or (iv) for any transaction from which the director derived an improper personal benefit. The Registrant’s amended and restated certificate of incorporation provides for such limitation of liability.

    The Registrant maintains standard policies of insurance under which coverage is provided (a) to the Registrant’s directors and officers against loss arising from claims made by reason of breach of duty or other wrongful act, and (b) to the Registrant with respect to payments the Registrant may make to its officers and directors pursuant to the above indemnification provision or otherwise as a matter of law.

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

    Not applicable.


    ITEM 8. EXHIBITS

     

    Exhibit
    Number
      

    Exhibit Description

       Incorporated by Reference      Filed
    Herewith
     
       Form      File No.      Exhibit
    No.
         Filed On     

     

     
    4.1    Amended and Restated Certificate of Incorporation      8-K        001-38890        3.1        5/13/2019        —    
    4.2    Amended and Restated Bylaws      8-K        001-38890        3.2        5/13/2019        —    
    5.1    Opinion of Cooley LLP      —          —          —          —          X  
    23.1    Consent of Independent Registered Public Accounting Firm      —          —          —          —          X  
    23.2    Consent of Cooley LLP (included in Exhibit 5.1)      —          —          —          —          X  
    24.1    Power of Attorney (included on the signature page to this registration statement)      —          —          —          —          X  
    99.1    Cortexyme, Inc. 2022 Inducement Plan      —          —          —          —          X  
    99.2    Forms of Stock Option Award Agreement, Notice of Stock Option Grant and Exercise Notice under Cortexyme, Inc. 2022 Inducement Plan      —          —          —          —          X  
    99.3    Forms of Restricted Stock Unit Award Agreement and Notice of Restricted Stock Unit Grant Cortexyme, Inc. 2022 Inducement Plan      —          —          —          —          X  
    99.4    Novosteo Inc. 2019 Equity Incentive Plan      —          —          —          —          X  
    107    Filing Fee Table                  X  

    ITEM 9. UNDERTAKINGS

    (a) The Registrant hereby undertakes:

    (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) (§ 230.424(b) of this chapter) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;


    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement.

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this Registration Statement.

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

    (b) The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

    (c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on May 20, 2022.

     

    CORTEXYME, INC.
    By:  

    /s/ Dirk Thye

      Dirk Thye
      Chief Executive Officer, Director


    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Dirk Thye, Christopher Lowe and Caryn McDowell, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures

     

    Title

     

    Date

    /s/ Dirk Thye, M.D.

     

    Chief Executive Officer and Director

    (Principal Executive Officer)

      May 20, 2022
    Dirk Thye, M.D.  

    /s/ Christopher Lowe

    Christopher Lowe

      Chief Financial Officer and Chief Operating Officer and Director (Principal Financial Officer)   May 20, 2022

    /s/ Ted Monohon

    Ted Monohon

     

    Chief Accounting Officer and Vice President, Finance

    (Principal Accounting Officer)

      May 20, 2022

    /s/ David A. Lamond

    David A. Lamond

      Director   May 20, 2022

    /s/ Philip S. Low, Ph.D.

      Director   May 20, 2022
    Philip S. Low, Ph.D.    

    /s/ Margaret McLoughlin, Ph.D.

    Margaret McLoughlin, Ph.D.

      Director   May 20, 2022

    /s/ Una Ryan, OBE, Ph.D.

    Una Ryan, OBE, Ph.D.

      Director   May 20, 2022

    /s/ Christopher J. Senner

    Christopher J. Senner

      Director   May 20, 2022

    /s/ Marwan Sabbagh, M.D.

    Marwan Sabbagh, M.D.

      Director   May 20, 2022
    Get the next $CRTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRTX

    DatePrice TargetRatingAnalyst
    3/9/2022$30.00 → $15.00Buy
    HC Wainwright & Co.
    1/28/2022$75.00 → $12.00Buy → Hold
    Canaccord Genuity
    1/28/2022Buy → Hold
    Canaccord Genuity
    1/27/2022Mkt Outperform → Mkt Perform
    JMP Securities
    10/27/2021Neutral → Underperform
    B of A Securities
    10/27/2021$58.00 → $15.00Neutral → Underperform
    BofA Securities
    10/27/2021$200.00 → $30.00Buy
    HC Wainwright & Co.
    9/16/2021$75.00 → $150.00Buy
    Canaccord Genuity
    More analyst ratings

    $CRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Cortexyme with a new price target

    HC Wainwright & Co. reiterated coverage of Cortexyme with a rating of Buy and set a new price target of $15.00 from $30.00 previously

    3/9/22 6:45:17 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Cortexyme from Buy to Hold and set a new price target of $12.00 from $75.00 previously

    1/28/22 7:19:09 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme downgraded by Canaccord Genuity

    Canaccord Genuity downgraded Cortexyme from Buy to Hold

    1/28/22 6:06:43 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    SEC Filings

    View All

    Cortexyme Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    12/16/22 4:04:17 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Cortexyme Inc.

    10-Q - Quince Therapeutics, Inc. (0001662774) (Filer)

    11/9/22 4:17:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Inc. filed SEC Form 8-K: Leadership Update

    8-K - Quince Therapeutics, Inc. (0001662774) (Filer)

    9/30/22 5:08:03 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,640 shares, decreasing direct ownership by 5% to 29,311 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    12/7/22 5:37:47 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Monohon Ted covered exercise/tax liability with 1,520 shares, decreasing direct ownership by 5% to 30,951 units to cover taxes

    4 - Quince Therapeutics, Inc. (0001662774) (Issuer)

    9/8/22 5:58:12 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Monohon Ted

    4 - Cortexyme, Inc. (0001662774) (Issuer)

    7/1/22 5:03:16 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022

    New ticker symbol (NASDAQ:QNCX) to initiate trading on August 1, 2022 Cortexyme, Inc. (NASDAQ:CRTX) today announced that the company's planned corporate name change to Quince Therapeutics is expected take effect on Monday, August 1, 2022. In conjunction with the corporate name change, the company plans to issue a news release that will provide a business update detailing Quince Therapeutics' go-forward growth strategy and development pipeline plans. Additionally, the company's ticker symbol on the Nasdaq Global Select Market is expected change to "QNCX" effective at the open of market trading on Monday, August 1, 2022. The company's common stock will continue to trade under the ticker sym

    7/27/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588

    Once daily dose of COR588 over 10-day period well-tolerated with no serious adverse events observed Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today reported the successful completion of its Phase 1 single ascending dose and multiple ascending dose (SAD/MAD) clinical trial of COR588, the company's lysine gingipain inhibitor in development for the treatment of Alzheimer's disease and indications with disease pathology associated with the keystone pathogen P. gingivalis. The study was a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, an

    7/27/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on advancing therapeutics for rare and degenerative diseases, today announced new preclinical data demonstrating the efficacy of the company's 3CLpro inhibitor, COR803, for treatment of coronavirus infections, including COVID-19 disease, caused by SARS-CoV-2 infection. In ongoing preclinical research, COR803 successfully reduced viral load of SARS-CoV-2 in vivo after oral treatment. COR803 is a novel small molecule 3CLpro inhibitor discovered and developed by Cortexyme based on its expertise in cysteine protease inhibition. 3CLpro, or Mpro, is a validated antiviral drug target shown to be essential in viral r

    6/21/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Cortexyme Appoints June Bray to its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company focused on rare and degenerative diseases, today announced the appointment of June Bray, a pharmaceutical industry veteran and global drug development and regulatory process expert, to the company's Board of Directors. "We are very pleased to welcome a seasoned pharmaceutical and global regulatory expert of June Bray's caliber to our Board of Directors," said David Lamond, chairperson of Cortexyme's Board of Directors. "With more than four decades of pharmaceutical industry experience, we look forward to her valuable contribution and perspective across multiple therapeutic areas." "I am excited to join Cortexyme's B

    6/13/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Appoints Dr. Philip Low to Its Board of Directors

    Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company pioneering therapeutic approaches to improve the lives of patients diagnosed with degenerative diseases, today announced the appointment of Dr. Philip S. Low, a renowned targeted drug discovery researcher and veteran biotech entrepreneur, to the company's Board of Directors. "In conjunction with today's acquisition of Novosteo, we are very pleased to welcome a distinguished researcher, innovator, and entrepreneur of Dr. Philip Low's caliber to our Board of Directors," said David Lamond, chairman of Cortexyme's Board of Directors. "His vast expertise across targeted drug discovery, prolific research abilities, and pro

    5/20/22 8:01:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Cortexyme Announces Agreement to Acquire Novosteo

    Expanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline Cortexyme, Inc. (NASDAQ:CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today announced that it entered into an agreement under which the company plans to acquire Novosteo, a privately-held biotech company focused on targeted therapeutics to treat rare skelet

    5/10/22 8:00:00 AM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Financials

    Live finance-specific insights

    View All

    Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer's Disease Progression

    In overall population, co-primary endpoints of ADAS-Cog11 and ADCS-ADL were not met Pre-specified subgroups representing up to half of the participants based on P. gingivalis infection level showed approximately 50% slowing of cognitive decline Clinical data validated upstream mechanism of action and benefits of targeting P. gingivalis Additional top-line GAIN Trial results to be presented at CTAD 2021 on November 11th Cortexyme to host investor conference call today Tuesday, October 26th at 4:30 p.m. Eastern Time Cortexyme, Inc. (NASDAQ:CRTX) today reported top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat

    10/26/21 4:01:00 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    7/8/22 12:56:11 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 2:48:42 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Cortexyme Inc. (Amendment)

    SC 13G/A - Cortexyme, Inc. (0001662774) (Subject)

    2/11/22 12:22:48 PM ET
    $CRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care